Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASRT NASDAQ:ELUT NASDAQ:JAN NASDAQ:UNCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$0.81+1.0%$0.75$0.51▼$1.38$77.49M0.35173,397 shs143,737 shsELUTElutia$1.28-2.3%$2.04$1.28▼$5.12$55.54M0.89160,796 shs410,670 shsJANJanOne$2.57$0.22▼$5.26$20.03M2.16229,417 shs139,500 shsUNCYUnicycive Therapeutics$3.87-5.4%$4.42$3.40▼$11.00$72.24M1.87469,071 shs1.17 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio+1.01%+1.94%+0.12%+28.71%-35.96%ELUTElutia-2.29%-31.91%-40.74%-28.09%-70.51%JANJanOne0.00%0.00%0.00%0.00%0.00%UNCYUnicycive Therapeutics-5.38%-11.24%-12.24%-43.21%-3.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$0.81+1.0%$0.75$0.51▼$1.38$77.49M0.35173,397 shs143,737 shsELUTElutia$1.28-2.3%$2.04$1.28▼$5.12$55.54M0.89160,796 shs410,670 shsJANJanOne$2.57$0.22▼$5.26$20.03M2.16229,417 shs139,500 shsUNCYUnicycive Therapeutics$3.87-5.4%$4.42$3.40▼$11.00$72.24M1.87469,071 shs1.17 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio+1.01%+1.94%+0.12%+28.71%-35.96%ELUTElutia-2.29%-31.91%-40.74%-28.09%-70.51%JANJanOne0.00%0.00%0.00%0.00%0.00%UNCYUnicycive Therapeutics-5.38%-11.24%-12.24%-43.21%-3.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASRTAssertio 2.33Hold$2.38192.02% UpsideELUTElutia 3.00Buy$7.00446.88% UpsideJANJanOne 0.00N/AN/AN/AUNCYUnicycive Therapeutics 3.33Buy$60.001,450.39% UpsideCurrent Analyst Ratings BreakdownLatest JAN, ELUT, ASRT, and UNCY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025ELUTElutiaLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $6.008/25/2025ASRTAssertioZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell8/12/2025ASRTAssertioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.50 ➝ $3.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASRTAssertio$117.10M0.67$0.05 per share16.40$1.27 per share0.64ELUTElutia$24.38M2.23N/AN/A($1.31) per share-0.98JANJanOne$39.61M0.00N/AN/A($0.67) per share0.00UNCYUnicycive Therapeutics$680K100.51N/AN/A$0.72 per share5.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASRTAssertio-$21.58M-$0.45N/A27.11N/A-36.97%-38.19%-15.45%11/10/2025 (Estimated)ELUTElutia-$53.95M-$1.06N/AN/AN/A-90.01%N/A-54.08%11/13/2025 (Estimated)JANJanOne-$7.81MN/A0.00N/AN/AN/A-359.71%-70.26%N/AUNCYUnicycive Therapeutics-$36.73M-$4.12N/AN/AN/AN/A-243.13%-119.46%11/12/2025 (Estimated)Latest JAN, ELUT, ASRT, and UNCY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ELUTElutia-$0.17-$0.26-$0.09-$0.26$6.55 million$6.26 million8/14/2025Q2 2025UNCYUnicycive Therapeutics-$0.70-$0.52+$0.18-$0.52N/AN/A8/11/2025Q2 2025ASRTAssertio-$0.10-$0.17-$0.07-$0.17$27.86 million$29.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASRTAssertioN/AN/AN/AN/AN/AELUTElutiaN/AN/AN/AN/AN/AJANJanOneN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASRTAssertio0.421.591.34ELUTElutiaN/A0.590.45JANJanOneN/A0.150.15UNCYUnicycive TherapeuticsN/A2.182.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASRTAssertio48.96%ELUTElutia74.03%JANJanOne6.27%UNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipASRTAssertio4.00%ELUTElutia27.60%JANJanOne3.00%UNCYUnicycive Therapeutics10.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASRTAssertio2096.24 million92.39 millionOptionableELUTElutia18042.40 million30.69 millionNot OptionableJANJanOne1708.98 million8.71 millionNot OptionableUNCYUnicycive Therapeutics917.66 million15.77 millionNot OptionableJAN, ELUT, ASRT, and UNCY HeadlinesRecent News About These CompaniesINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics4 hours ago | prnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCYSeptember 13 at 10:00 AM | prnewswire.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure ...September 12 at 12:22 AM | bakersfield.comBROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Fraud Lawsuit – UNCYSeptember 12 at 7:42 PM | globenewswire.comClass Action Lawsuit Filed Against Unicycive Therapeutics, Inc. (UNCY) - Recover Losses - Contact Levi & Korsinsky Before October 14, 2025September 12 at 2:19 PM | theglobeandmail.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive TherapeuticsSeptember 12 at 9:40 AM | globenewswire.comOctober 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against UNCYSeptember 12 at 8:45 AM | prnewswire.comUNCY Investors have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud LawsuitSeptember 11 at 5:03 PM | prnewswire.comLevi & Korsinsky Reminds Unicycive Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 14, 2025 – UNCYSeptember 11 at 4:22 PM | globenewswire.comRosen Law Firm Urges Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Stockholders with Large Losses to Contact the Firm for Information About Their RightsSeptember 11 at 2:01 PM | businesswire.comInvestors in Unicycive Therapeutics, Inc. Should Contact The Gross Law Firm Before October 14, 2025 to Discuss Your Rights - UNCYSeptember 11 at 8:45 AM | prnewswire.comLevi & Korsinsky Notifies Shareholders of Unicycive Therapeutics, Inc. (UNCY) of a Class Action Lawsuit and an Upcoming DeadlineSeptember 10 at 7:11 PM | theglobeandmail.comShareholders that lost money on Unicycive Therapeutics, Inc. (UNCY) Urged to Join Class Action – Contact The Gross Law Firm to Learn MoreSeptember 10 at 3:45 PM | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers – UNCYSeptember 10 at 10:00 AM | globenewswire.comUnicycive Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 14, 2025 to Discuss Your Rights - UNCYSeptember 9, 2025 | theglobeandmail.comUnicycive Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Unicycive Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 14, 2025 - UNCYSeptember 9, 2025 | prnewswire.comLevi & Korsinsky Notifies Unicycive Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – UNCYSeptember 8, 2025 | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCYSeptember 8, 2025 | prnewswire.comUNCY LAWSUIT ALERT: The Gross Law Firm Notifies Unicycive Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineSeptember 8, 2025 | prnewswire.comShareholders That Lost Money on Unicycive Therapeutics, Inc. (UNCY) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreSeptember 7, 2025 | theglobeandmail.comNantahala Capital Management LLC Sells 1,000,000 Shares of Unicycive Therapeutics, Inc. $UNCYSeptember 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJAN, ELUT, ASRT, and UNCY Company DescriptionsAssertio NASDAQ:ASRT$0.81 +0.01 (+1.01%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.81 0.00 (-0.41%) As of 09/12/2025 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Elutia NASDAQ:ELUT$1.28 -0.03 (-2.29%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$1.28 0.00 (0.00%) As of 09/12/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.JanOne NASDAQ:JANJanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.Unicycive Therapeutics NASDAQ:UNCY$3.87 -0.22 (-5.38%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.90 +0.03 (+0.90%) As of 09/12/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
